文献速递冠心病

全人群随机评估永久聚合物佐他莫司洗脱支架与无聚合物两性霉素洗脱支架的对比

Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.
PubMed 文献 · Circulation · 2019-01-01

在3个欧洲中心纳入1502例需PCI的全人群患者,随机1:1比较永久聚合物佐他莫司洗脱支架(PP-ZES)与无聚合物两性霉素洗脱支架(PF-AES)的12个月靶病变失败率。PF-AES不劣于PP-ZES(风险差0.5%,单侧95%CI上限2.6%,非劣效P=0.0086)。

要点

  • PF-AES在12个月靶病变失败方面非劣效于PP-ZES。
  • 两组心脏死亡、靶血管心梗和靶病变血运重建率差异无统计学意义。
  • 总体明确或 probable 支架血栓发生率为1.0%。

核心结论

  • PF-AES在12个月靶病变失败方面非劣效于PP-ZES。

研究设计与样本

  • 研究者发起的前瞻性、多中心、随机、非劣效性试验,纳入3个欧洲中心需PCI的全人群患者。
  • 按肌钙蛋白状态和糖尿病分层后1:1随机分配至PP-ZES或PF-AES,共1502例随机,1491例接受指定支架并可随访。
  • 主要终点为12个月靶病变失败(心源性死亡、靶血管心梗或靶病变血运重建),采用改良意向性治疗分析,80%把握度,非劣效界值3.5%。

主要发现

  • 主要终点在PP-ZES组744例中发生42例(5.6%),PF-AES组747例中发生46例(6.2%)。
  • PF-AES临床非劣效于PP-ZES(风险差0.5%;单侧95%CI上限2.6%;非劣效P=0.0086)。
  • 心脏死亡PP-ZES组10例(1.3%)vs PF-AES组10例(1.3%),差异P=1.00。
  • 靶血管心梗PP-ZES组18例(2.4%)vs PF-AES组17例(2.3%),差异P=0.87。
  • 靶病变血运重建PP-ZES组22例(2.9%)vs PF-AES组20例(2.6%),差异P=0.75;总体明确或 probable 支架血栓发生率为1.0%。

临床怎么用

  • 在需PCI的全人群患者中,PF-AES可作为PP-ZES的替代选择,12个月靶病变失败风险非劣效。

局限性

  • 原文未报告局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polymer-free amphilimus-eluting stents (PF-AES) represent a novel elution technology in the current era of drug-eluting stents. The clinical safety and efficacy of PF-AES as compared with latest-generation permanent-polymer zotarolimus-eluting stents (PP-ZES) have not yet been investigated in a large randomized trial. METHODS: In this physician-initiated, prospective, multicenter, randomized, noninferiority trial, an all-comers population requiring percutaneous coronary intervention was enrolled across 3 European sites. Randomization (1:1 ratio) to PP-ZES or PF-AES was performed after stratification for troponin status and diabetes mellitus. In both treatment arms, troponin-positive patients were planned for 12-month dual antiplatelet therapy, whereas troponin-negative patients were planned for 1-month dual antiplatelet therapy. Outcome assessors were blinded to the allocated treatment. The device-oriented primary end point of target-lesion failure was defined as cardiac death, target-vessel myocardial infarction, or target-lesion revascularization at 12-months as analyzed by modified intention-to-treat (80% power, and a 3.5% noninferiority margin). RESULTS: In total, 1502 patients were randomized and 1491 treated with the assigned stent and available for follow-up. The primary end point occurred in 42 (5.6%) of the 744 patients receiving PP-ZES versus 46 (6.2%) of the 747 patients receiving PF-AES. PF-AES were clinically noninferior to PP-ZES (risk difference, 0.5%; upper limit 1-sided 95% confidence interval, 2.6%; Pnoninferiority=0.0086). Cardiac death occurred in 10 (1.3%) versus 10 patients (1.3%; P value for difference, 1.00), target-vessel myocardial infarction occurred in 18 (2.4%) versus 17 patients (2.3%; P value for difference, 0.87), and target-lesion revascularization occurred in 22 (2.9%) versus 20 patients (2.6%; P value for difference, 0.75) for PF-AES as compared with PP-ZES. Overall, definite or probable stent thrombosis occurred in 1.0%. CONCLUSIONS: PF-AES were noninferior to PP-ZES regarding target-lesion failure at 12 months. Findings regarding the secondary end point and prespecified subgroups were generally consistent with that of the primary end point. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02328898.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Rozemeijer R, Stein M, Voskuil M, et al. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent. Circulation. 2019. PMID: 30586704. doi:10.1161/CIRCULATIONAHA.118.037707

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。